Biodesix Inc
BDSX
Get informed when a big investor buys or sells
+ FollowMarket Cap$219.5M
Close$
Share Statistics
| Market cap | $219.50 Million |
|---|---|
| Enterprise Value | $261.51 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-4.67 |
| Beta | 0.6 |
| Outstanding Shares | 10,296,000 |
Return
| Return on Equity | -303.61% |
|---|---|
| Return on Assets | -29.12% |
| Return on Invested Capital | -25.80% |
Valuation & Multiples
| P/E Ratio | -8.51 |
|---|---|
| PEG | 23.25 |
| Price to Sales | 3.04 |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 2.54 |
| Enterprise Value to EBIT | -12.67 |
| Enterprise Value to Net Income | -10 |
| Total Debt to Enterprise | 0.28 |
| Debt to Equity | 7.87 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 6, 2026
EPS Estimate
$-0.86
Average shareholder expectationRevenue Estimate
$26.03 M
Average shareholder expectationNext Earnings Call
Expected Date
November 2, 2026
EPS Estimate
$-0.74
Average shareholder expectationRevenue Estimate
$27.55 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 39.65%▲ 2.21% |
|---|---|
| Total Invested | $92.06M▲ 75.60% |
| Investors Holding | 45▲ 4.00% |
ESG Score
No data
About Biodesix Inc
200 employeesBiodesix, Inc. operates as a biotechnology company. The Company offers non-small cell lung cancer pretreatment serum tests and laboratory testing. Biodesix provides diagnostic tools and equipment for blood and tissue analysis in the United States.